<DOC>
	<DOC>NCT01014013</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of ertapenem sodium (Invanz) in treatment of complicated urinary tract infections with respect to the proportion of patients with a favorable microbiological response at 5-9 days post therapy.</brief_summary>
	<brief_title>Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Adult patients with a suspected or documented complicated urinary tract infection Female patients must test negative for pregnancy and agree to use adequate birth control measures Nursing women must agree to defer breastfeeding until 5 days after completion of all study antibiotic therapy Patients with complete obstruction of any portion of the urinary tract Patients with rapidly progressive or terminal illness Renal transplant patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>